A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.
Overview
David Malcom Rodman, the chief medical officer at Mineralys Therapeutics, Inc. (NASDAQ:MLYS), executed a sale of 20,407 shares of common stock on July 13 and July 15, 2026, for a total value of $557,000, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($27.28); post-transaction value based on July 15, 2026 market close ($27.31).
Details
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a market capitalization of $2 billion, currently advancing innovative aldosterone synthase inhibitors through clinical development. The company's focused pipeline addresses a significant unmet medical need in cardiovascular therapeutics, with lorundrostat positioned as a differentiated treatment option for resistant hypertension. With a concentrated research and development strategy, Mineralys is positioned to capture market opportunity in the high-value cardiovascular therapeutic space upon successful clinical and regulatory milestones.
Source
Originally published at www.fool.com.